Lilly's Diabetes Drug Candidate Tirzepatide Meets Primary Study Outcome In Surpass-4 Trial

Eli Lilly and Company (LLY) Thursday said its diabetes drug candidate tirzepatide met all primary and key secondary study outcomes in Surpass-4 trial.

Results from the Surpass-4 study showed that treatment with tirzepatide provided superior A1C reductions as well as weight loss compared to insulin glargine in adults with type 2 diabetes who have increased cardiovascular risk.

All three doses, 5 mg, 10 mg and 15 mg of tirzepatide reduced A1C and body weight, with the highest dose of tirzepatide reducing A1C by 2.58 percent and body weight by 11.7 kg, Lilly said.

The most commonly reported adverse events during the study were mild to moderate gastrointestinal side effects.

Tirzepatide is a novel investigational once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist that integrates the actions of the GIP and GLP-1 incretins into a single molecule, representing a new class of medicines being studied for the treatment of type 2 diabetes.

Lilly plans to submit the registration package to regulatory authorities by the end of 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of HSBC Holdings Plc were gaining in London and Hong Kong trading after the Asia-focused lender reported Monday that its first-half profit more than doubled, despite weak revenues. Looking ahead, the company said while uncertainties remain, the outlook is more positive with evidence of growth in strategic areas. After Disney World, retail giant Walmart Inc. (WMT) makes it mandatory for all its employees to wear mask on their facilities in the "high-risk" states where the Delta variant of Coronavirus has become menacing. The orders will be in effect immediately. The Center for Disease Control and Prevention... Generac Power Systems is recalling 325,735 units of Generac and DR 6500 Watt and 8000 Watt portable generators for potential risk of finger amputation and crushing hazards, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. These include 4,575 units sold in Canada.
Follow RTT